CURRENT UNDERSTANDING OF VITILIGO: A COMPREHENSIVE LITERATURE REVIEW
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.5355Keywords:
Vitiligo, Depigmentation Disorders, Melanocyte Autoimmunity, JAK Inhibitors, IFN-γ-Chemokine Axis, Quality of LifeAbstract
Introduction and Purpose: Vitiligo is a chronic, acquired autoimmune disorder characterized by the selective destruction of melanocytes, leading to the appearance of well-defined depigmented patches affecting the skin and mucous membranes. It is estimated to affect approximately 0.5 – 2% of the global population. Even though it was once regarded as mainly a cosmetic condition, now it is increasingly being recognized as a systemic disease with substantial psychological consequences. This review aims to summarize current knowledge regarding its genetic background, key immunological pathways and the emerging therapeutic approaches, constantly reshaping patient outcomes.
Description of The State of Knowledge: Recent research has highlighted the complex nature of vitiligo pathogenesis, involving oxidative stress, genetic predisposition and immune-mediated mechanisms. In particular, the IFN-γ-chemokine axis, including CXCL9 and CXCL10, appears to play a central role in melanocyte loss. Clinically, Segmental Vitiligo usually follows a unilateral, dermatomal pattern and is often linked to somatic mosaicism, whereas Non-segmental Vitiligo remains as the most common form and typically presents with symmetrical distribution. Diagnostic precision has also advanced, through the introduction of non-invasive imaging techniques, including reflectance confocal microscopy and molecular biomarkers. From a therapeutic perspective, treatment strategies have moved beyond traditional phototherapy and topical agents to targeted interventions, most notably Janus Kinase inhibitors with ruxolitinib, representing one of the most promising options. Surgical procedures may also be considered in carefully selected patients with stable disease.
Conclusions: Despite remaining a challenging dermatological condition, the progress made in understanding the immunological and molecular mechanisms underlying vitiligo, has opened new possibilities for more targeted and effective treatment. The modern approach increasingly combines precise diagnostic evaluation with individualized therapeutic strategies. Effective management now requires a holistic approach that balances both medical and psychological aspects faced by patients.
References
Bergqvist, C., & Ezzedine, K. (2020). Vitiligo: A review. Dermatology, 236(6), 571–592. https://doi.org/10.1159/000506103
Ezzedine, K., Eleftheriadou, V., Whitton, M., & van Geel, N. (2015). Vitiligo. Lancet, 386(9988), 74–84. https://doi.org/10.1016/S0140-6736(14)60763-7
Ezzedine, K., Tannous, R., Pearson, T. F., & Harris, J. E. (2025). Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity. Journal of Clinical Investigation, 135(2), e185785. https://doi.org/10.1172/JCI185785
Abdi, P., Anthony, M. R., Farkouh, C., Chan, A. R., Kooner, A., Qureshi, S., & Maibach, H. (2023). Non-invasive skin measurement methods and diagnostics for vitiligo: A systematic review. Frontiers in Medicine, 10, 1200963. https://doi.org/10.3389/fmed.2023.1200963
Liang, X., Guo, F., Fan, Q., Cai, X., Wang, J., Chen, J., Liu, F., Du, Y., Chen, Y., & Li, X. (2024). Healthy lifestyle choices: New insights into vitiligo management. Frontiers in Immunology, 15, 1440705. https://doi.org/10.3389/fimmu.2024.1440705
Rodrigues, M., Ezzedine, K., Hamzavi, I., Pandya, A. G., Harris, J. E., & Vitiligo Working Group. (2017). New discoveries in the pathogenesis and classification of vitiligo. Journal of the American Academy of Dermatology, 77(1), 1–13. https://doi.org/10.1016/j.jaad.2016.10.048
Iwanowski, T., Kołkowski, K., Nowicki, R. J., & Sokołowska-Wojdyło, M. (2023). Etiopathogenesis and emerging methods for treatment of vitiligo. International Journal of Molecular Sciences, 24(11), 9749. https://doi.org/10.3390/ijms24119749
Huang, X., Zhu, J., Wei, T., Luo, L., Li, C., & Zhao, M. (2025). Epigenetic modifications in vitiligo. Clinical Reviews in Allergy & Immunology, 68(1), 39. https://doi.org/10.1007/s12016-025-09048-z
Liu, W., Ma, W., Xue, X., & Li, S. (2025). The neuro-endocrinal regulation in vitiligo. Pigment Cell & Melanoma Research, 38(4), e70029. https://doi.org/10.1111/pcmr.70029
Roberts, G. H. L., Santorico, S. A., & Spritz, R. A. (2020). The genetic architecture of vitiligo. Pigment Cell & Melanoma Research, 33(1), 8–15. https://doi.org/10.1111/pcmr.12848
Sandoval-Cruz, M., García-Carrasco, M., Sánchez-Porras, R., Mendoza-Pinto, C., Jiménez-Hernández, M., Munguía-Realpozo, P., & Ruiz-Argüelles, A. (2011). Immunopathogenesis of vitiligo. Autoimmunity Reviews, 10(12), 762–765. https://doi.org/10.1016/j.autrev.2011.02.004
Białczyk, A., Wełniak, A., Kamińska, B., & Czajkowski, R. (2023). Oxidative stress and potential antioxidant therapies in vitiligo: A narrative review. Molecular Diagnosis & Therapy, 27(6), 723–739. https://doi.org/10.1007/s40291-023-00672-z
Lin, X., Meng, X., & Lin, J. (2025). Segmental vitiligo: Autoimmune pathogenesis, neuronal mechanisms, and somatic mosaicism. International Journal of Dermatology, 64(3), 490–498. https://doi.org/10.1111/ijd.17627
Speeckaert, R., Lambert, J., Bulat, V., Belpaire, A., Speeckaert, M., & van Geel, N. (2020). Autoimmunity in segmental vitiligo. Frontiers in Immunology, 11, 568447. https://doi.org/10.3389/fimmu.2020.568447
Harris, J. E. (2017). Chemical-induced vitiligo. Dermatologic Clinics, 35(2), 151–161. https://doi.org/10.1016/j.det.2016.11.006
Akl, J., Lee, S., Ju, H. J., Parisi, R., Kim, J. Y., Jeon, J. J., Heo, Y. W., Eleftheriadou, V., Hamzavi, I., Griffiths, C. E. M., Ashcroft, D. M., Mysore, V., Gupta, S., Parsad, D., Lim, H., Bae, J. M., Ezzedine, K., & Global Vitiligo Atlas. (2024). Estimating the burden of vitiligo: A systematic review and modelling study. Lancet Public Health, 9(6), e386–e396. https://doi.org/10.1016/S2468-2667(24)00026-4
Ezzedine, K., Eleftheriadou, V., Jones, H., Bibeau, K., Kuo, F. I., Sturm, D., & Pandya, A. G. (2021). Psychosocial effects of vitiligo: A systematic literature review. American Journal of Clinical Dermatology, 22(6), 757–774. https://doi.org/10.1007/s40257-021-00631-6
Papaccio, F., Ottaviani, M., Truglio, M., D'Arino, A., Caputo, S., Pacifico, A., Iacovelli, P., Di Nardo, A., Picardo, M., & Bellei, B. (2024). Markers of metabolic abnormalities in vitiligo patients. International Journal of Molecular Sciences, 25(18), 10201. https://doi.org/10.3390/ijms251810201
Lotti, T., & D'Erme, A. M. (2014). Vitiligo as a systemic disease. Clinics in Dermatology, 32(3), 430–434. https://doi.org/10.1016/j.clindermatol.2013.11.011
Perez-Bootello, J., Cova-Martin, R., Naharro-Rodriguez, J., & Segurado-Miravalles, G. (2023). Vitiligo: Pathogenesis and new and emerging treatments. International Journal of Molecular Sciences, 24(24), 17306. https://doi.org/10.3390/ijms242417306
Failla, C. M., Carbone, M. L., Fortes, C., Pagnanelli, G., & D'Atri, S. (2019). Melanoma and vitiligo: In good company. International Journal of Molecular Sciences, 20(22), 5731. https://doi.org/10.3390/ijms20225731
Rooker, A., Ouwerkerk, W., Bekkenk, M. W., Luiten, R. M., & Bakker, W. J. (2024). The risk of keratinocyte cancer in vitiligo and the potential mechanisms involved. Journal of Investigative Dermatology, 144(2), 234–242. https://doi.org/10.1016/j.jid.2023.08.012
Kussainova, A., Kassym, L., Akhmetova, A., Glushkova, N., Sabirov, U., Adilgozhina, S., Tuleutayeva, R., & Semenova, Y. (2020). Vitiligo and anxiety: A systematic review and meta-analysis. PLOS ONE, 15(11), e0241445. https://doi.org/10.1371/journal.pone.0241445
Maamri, A., & Badri, T. (2021). Sexual disorders in patients with vitiligo. La Tunisie Médicale, 99(5), 504–505.
Nahhas, A. F., Mohammad, T. F., & Hamzavi, I. H. (2017). Vitiligo surgery: Shuffling melanocytes. Journal of Investigative Dermatology Symposium Proceedings, 18(2), S34–S37. https://doi.org/10.1016/j.jisp.2017.01.001
Frączek, A., Kasprowicz-Furmańczyk, M., Placek, W., & Owczarczyk-Saczonek, A. (2022). Surgical treatment of vitiligo. International Journal of Environmental Research and Public Health, 19(8), 4812. https://doi.org/10.3390/ijerph19084812
Cortelazzi, C., Pellacani, G., Raposio, E., & Di Nuzzo, S. (2020). Vitiligo management: Combination of surgical treatment and phototherapy under reflectance confocal microscopy monitoring. European Review for Medical and Pharmacological Sciences, 24(13), 7366–7371. https://doi.org/10.26355/eurrev_202007_21904
LeWitt, T., Tauscher, R., Obiofuma, G., Peterson, J., Haddadin, R., & Kundu, R. V. (2023). Ocular manifestations of vitiligo: A systematic review. BMC Ophthalmology, 23(1), 120. https://doi.org/10.1186/s12886-023-02777-9
Shao, X., Chen, T., Pan, X., Chen, S., Chen, Y., & Chen, J. (2024). Biologic drugs induced vitiligo: Case reports and review of literature. Frontiers in Immunology, 15, 1455050. https://doi.org/10.3389/fimmu.2024.1455050
Ghani, H., Tan, I. J., Ghofrani, S., Tchack, M., & Rao, B. (2025). Vitiligo: Ruxolitinib and other oral treatment options beyond ruxolitinib. Skin Research and Technology, 31(10), e70276. https://doi.org/10.1111/srt.70276
Zubair, R., & Hamzavi, I. H. (2020). Phototherapy for vitiligo. Dermatologic Clinics, 38(1), 55–62. https://doi.org/10.1016/j.det.2019.08.005
Daniel, B. S., & Wittal, R. (2015). Vitiligo treatment update. Australasian Journal of Dermatology, 56(2), 85–92. https://doi.org/10.1111/ajd.12256
Wang, X., Wu, W., Chen, J., Li, C., & Li, S. (2024). Management of the refractory vitiligo patient: Current therapeutic strategies and future options. Frontiers in Immunology, 14, 1294919. https://doi.org/10.3389/fimmu.2023.1294919
Al-Smadi, K., Ali, M., Alavi, S. E., Jin, X., Imran, M., Leite-Silva, V. R., & Mohammed, Y. (2023). Using a topical formulation of vitamin D for the treatment of vitiligo: A systematic review. Cells, 12(19), 2387. https://doi.org/10.3390/cells12192387
Qi, F., Liu, F., & Gao, L. (2021). Janus kinase inhibitors in the treatment of vitiligo: A review. Frontiers in Immunology, 12, 790125. https://doi.org/10.3389/fimmu.2021.790125
Feng, Y., & Lu, Y. (2022). Advances in vitiligo: Update on therapeutic targets. Frontiers in Immunology, 13, 986918. https://doi.org/10.3389/fimmu.2022.986918
Thakur, V., Bishnoi, A., Vinay, K., Kumaran, S. M., & Parsad, D. (2021). Vitiligo: Translational research and effective therapeutic strategies. Pigment Cell & Melanoma Research, 34(4), 814–826. https://doi.org/10.1111/pcmr.12974
Salloum, A., Bazzi, N., Maalouf, D., & Habre, M. (2020). Microneedling in vitiligo: A systematic review. Dermatologic Therapy, 33(6), e14297. https://doi.org/10.1111/dth.14297
Post, N. F., Ezekwe, N., Narayan, V. S., Bekkenk, M. W., Van Geel, N., Hamzavi, I., Passeron, T., & Wolkerstorfer, A. (2022). The use of lasers in vitiligo, an overview. Journal of the European Academy of Dermatology and Venereology, 36(6), 779–789. https://doi.org/10.1111/jdv.18005
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Michał Stachel, Karol Józef Szkarłat, Maksymilian Szklarski, Jędrzej Sztajura, Szymon Targosz, Weronika Szymacha, Aleksandra Płecka, Ewa Maraszewska, Karol Zimnicki, Alicja Stępień

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

